Jundishapur Journal of Microbiology

Published by: Kowsar

Single Chain Antibodies Against gp55 of Human Cytomegalovirus (HCMV) for Prophylaxis and Treatment of HCMV Infections

Bahareh Moazen 1 , Elahe Ebrahimi 3 and Foroogh Nejatollahi 2 , 3 , *
Authors Information
1 Student Research Committee, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Shiraz HIV/AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Department of Immunology, Recombinant Antibody Laboratory, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Jundishapur Journal of Microbiology: March 01, 2016, 9 (3); e16241
  • Published Online: March 15, 2016
  • Article Type: Research Article
  • Received: December 7, 2013
  • Revised: July 18, 2014
  • Accepted: July 23, 2014
  • DOI: 10.5812/jjm.16241

To Cite: Moazen B, Ebrahimi E, Nejatollahi F. Single Chain Antibodies Against gp55 of Human Cytomegalovirus (HCMV) for Prophylaxis and Treatment of HCMV Infections, Jundishapur J Microbiol. 2016 ; 9(3):e16241. doi: 10.5812/jjm.16241.

Copyright © 2016, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Freeman RJ. The 'indirect' effects of cytomegalovirus infection. Am J Transplant. 2009; 9(11): 2453-8[DOI][PubMed]
  • 2. Ziemann M, Sedemund-Adib B, Reiland P, Schmucker P, Hennig H. Increased mortality in long-term intensive care patients with active cytomegalovirus infection. Crit Care Med. 2008; 36(12): 3145-50[DOI][PubMed]
  • 3. Carrillo Esper R. [Citomegalovirus reactivation in critical ill intensive care patients]. Gac Med Mex. 2011; 147(2): 159-62[PubMed]
  • 4. Medina JC, Pérez-Sartori G, Caltenco-Serrano R, María Aguado J. Immunologic Response and Pathogenic Mechanisms of Cytomegalovirus Infection in Transplant Recipients. Trends Transplant. 2009; 3(2): 103-12
  • 5. Slyker JA, Lohman-Payne BL, John-Stewart GC, Maleche-Obimbo E, Emery S, Richardson B, et al. Acute cytomegalovirus infection in Kenyan HIV-infected infants. AIDS. 2009; 23(16): 2173-81[DOI][PubMed]
  • 6. Gerna G, Lilleri D, Furione M, Baldanti F. Management of human cytomegalovirus infection in transplantation: validation of virologic cut-offs for preemptive therapy and immunological cut-offs for protection. New Microbiol. 2011; 34(3): 229-54[PubMed]
  • 7. Puchhammer-Stöckl E, Görzer I. Human cytomegalovirus: an enormous variety of strains and their possible clinical significance in the human host. Future Virology. 2011; 6(2): 259-71[DOI]
  • 8. Knipe DM, Howley PM. Fields' virology. 2007;
  • 9. Elliott SP. Congenital cytomegalovirus infection: an overview. Infect Disord Drug Targets. 2011; 11(5): 432-6[PubMed]
  • 10. McGregor A. Current and new cytomegalovirus antivirals and novel animal model strategies. Inflamm Allergy Drug Targets. 2010; 9(4): 286-99[PubMed]
  • 11. Kotton CN. Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol. 2010; 6(12): 711-21[DOI][PubMed]
  • 12. Jacobsen T, Sifontis N. Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. Am J Health Syst Pharm. 2010; 67(17): 1417-25[DOI][PubMed]
  • 13. Van den Bosch GA, Ponsaerts P, Vanham G, Van Bockstaele DR, Berneman ZN, Van Tendeloo VF. Cellular immunotherapy for cytomegalovirus and HIV-1 infection. J Immunother. 2006; 29(2): 107-21[DOI][PubMed]
  • 14. Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SP. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J. 2002; 21(2): 133-8[PubMed]
  • 15. Bergallo M, Costa C, Gambarino S, Tornicelli A, Astegiano S, Terlizzi ME, et al. Human cytomegalovirus glycoprotein B genotyping from bronchoalveolar lavage specimens. Can J Microbiol. 2011; 57(4): 273-7[DOI][PubMed]
  • 16. Nejatollahi F, Hodgetts SJ, Vallely PJ, Burnie JP. Neutralising human recombinant antibodies to human cytomegalovirus glycoproteins gB and gH. FEMS Immunol Med Microbiol. 2002; 34(3): 237-44[PubMed]
  • 17. Nejatollahi F, Malek-Hosseini Z, Mehrabani D. Development of single chain antibodies to P185 tumor antigen. Iran Red Crescent Med J. 2008; 10(4): 298-302
  • 18. Weisser NE, Hall JC. Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnol Adv. 2009; 27(4): 502-20[DOI][PubMed]
  • 19. Zhang H. Empowering scFv with effector cell functions for improved anticancer therapeutics. Oncoimmunology. 2013; 2(6)[DOI][PubMed]
  • 20. Nejatollahi F, Jaberipour M, Asgharpour M. Triple blockade of HER2 by a cocktail of anti-HER2 scFv antibodies induces high antiproliferative effects in breast cancer cells. Tumour Biol. 2014; 35(8): 7887-95[DOI][PubMed]
  • 21. Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol. 2002; 13(6): 603-8[PubMed]
  • 22. Baek H, Suk KH, Kim YH, Cha S. An improved helper phage system for efficient isolation of specific antibody molecules in phage display. Nucleic Acids Res. 2002; 30(5)[PubMed]
  • 23. Ishibashi K, Tokumoto T, Shirakawa H, Hashimoto K, Ikuta K, Kushida N, et al. Lack of antibodies against the antigen domain 2 epitope of cytomegalovirus (CMV) glycoprotein B is associated with CMV disease after renal transplantation in recipients having the same glycoprotein H serotypes as their donors. Transpl Infect Dis. 2011; 13(3): 318-23[DOI][PubMed]
  • 24. Singh J, Compton T. Characterization of a panel of insertion mutants in human cytomegalovirus glycoprotein B. J Virol. 2000; 74(3): 1383-92[PubMed]
  • 25. Krauss S, Kaps J, Czech N, Paulus C, Nevels M. Physical requirements and functional consequences of complex formation between the cytomegalovirus IE1 protein and human STAT2. J Virol. 2009; 83(24): 12854-70[DOI][PubMed]
  • 26. Axelsson F, Adler SP, Lamarre A, Ohlin M. Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines. Vaccine. 2007; 26(1): 41-6[DOI][PubMed]
  • 27. Lillo AM, Ayriss JE, Shou Y, Graves SW, Bradbury AR, Pavlik P. Development of phage-based single chain Fv antibody reagents for detection of Yersinia pestis. PLoS One. 2011; 6(12)[DOI][PubMed]
  • 28. Krishnaswamy S, Kabir ME, Rahman MM, Miyamoto M, Furuichi Y, Komiyama T. Isolation and characterization of recombinant single chain fragment variable anti-idiotypic antibody specific to Aspergillus fumigatus membrane protein. J Immunol Methods. 2011; 366(1-2): 60-8[DOI][PubMed]
  • 29. Thathaisong U, Maneewatch S, Kulkeaw K, Thueng-In K, Poungpair O, Srimanote P, et al. Human monoclonal single chain antibodies (HuScFv) that bind to the polymerase proteins of influenza A virus. Asian Pac J Allergy Immunol. 2008; 26(1): 23-35[PubMed]
  • 30. Meyer T, Stratmann-Selke J, Meens J, Schirrmann T, Gerlach GF, Frank R, et al. Isolation of scFv fragments specific to OmpD of Salmonella Typhimurium. Vet Microbiol. 2011; 147(1-2): 162-9[DOI][PubMed]
  • 31. Urushibata Y, Itoh K, Ohshima M, Seto Y. Generation of Fab fragment-like molecular recognition proteins against staphylococcal enterotoxin B by phage display technology. Clin Vaccine Immunol. 2010; 17(11): 1708-17[DOI][PubMed]
  • 32. Zhang JL, Gou JJ, Zhang ZY, Jing YX, Zhang L, Guo R, et al. Screening and evaluation of human single-chain fragment variable antibody against hepatitis B virus surface antigen. Hepatobiliary Pancreat Dis Int. 2006; 5(2): 237-41[PubMed]
  • 33. Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, et al. A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antiviral Res. 2004; 64(2): 103-11[DOI][PubMed]
  • 34. Jun F, Minhuan L, Yadan M, Yaping H, Hanying L, Jianhua H, et al. Development of two potential diagnostic monoclonal antibodies against human cytomegalovirus glycoprotein B. Braz J Med Biol Res. 2012; 45(7): 583-90[PubMed]
  • 35. Wadhawan M, Gupta S, Goyal N, Vasudevan KR, Makki K, Dawar R, et al. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience. Liver Transpl. 2012; 18(12): 1448-55[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments